期刊文献+

晚期肺腺癌患者不同血清癌胚抗原浓度梯度与EGFR-TKI疗效及预后的关系 被引量:10

在线阅读 下载PDF
导出
摘要 目的探讨晚期肺腺癌患者不同血清癌胚抗原浓度梯度与表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKI)疗效以及预后的关系。方法 78例晚期肺腺癌患者,分别以5、200 ng/mL为分界点进行分组,分析3组患者口服EGFR-TKI(厄罗替尼或吉非替尼)的疗效和生存资料。结果血清CEA≤5 ng/mL组患者的疾病控制率(CR+PR+SD)为45.1%,无疾病进展时间为5.6个月,中位生存时间为8.9个月;5 ng/mL<CEA≤200 ng/mL组患者的疾病控制率为81.6%,无疾病进展时间为9.7个月,中位生存时间为12.9个月;CEA>200 ng/mL组患者的疾病控制率为44.4%,无疾病进展时间为4.8个月,中位生存时间为8.4个月。3组患者的疾病控制率、无疾病进展时间、中位生存时间差异有统计学意义。结论晚期肺腺癌患者,服用EGFR-TKI前不同血清CEA浓度梯度,提示不同的EGFR-TKI疗效和预后。当5 ng/mL<CEA≤200 ng/mL时提示较好的疗效和预后,当血清CEA≤5 ng/mL和CEA>200 ng/mL时提示较差的疗效和预后。
出处 《广东医学》 CAS CSCD 北大核心 2013年第1期82-84,共3页 Guangdong Medical Journal
  • 相关文献

参考文献14

  • 1MOK T S,WU Y L,THONGPRASERT S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].New England Journal of Medicine,2009,(10):947-957.
  • 2ZHOU C C,WU Y L,CHEN G Y. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802):a multicentre,open-label,randomised,phase 3 study[J].Lancet Oncology,2011,(08):735-742.
  • 3GOW C H,CHANG Y L,HSU Y C. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer[J].Annals of Oncology,2009,(04):696-702.doi:10.1093/annonc/mdn679.
  • 4赵玲娣,石远凯.血清癌胚抗原在非小细胞肺癌中的作用与地位[J].癌症进展,2011,9(3):279-283. 被引量:8
  • 5王宏羽,屈风莲,张湘茹,周云飞,储大同,孙燕.血清CEA、NSE、Cyfra21-1水平与肺癌分期、近期疗效及生存时间的相关性研究[J].癌症进展,2004,2(4):295-298. 被引量:7
  • 6SHOJI F,YOSHINO L,YANO T. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas[J].Cancer,2007,(12):2793-2798.
  • 7ZHAO L D,LI J L,WANG Y. Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer[J].Zhonghua Zhongliu Zazhi,2011,(03):217-221.
  • 8李醒亚,成媛,刘杰,申淑景,贾永旭.非小细胞肺癌患者血清CEA水平与EGFR-TKI疗效的关系[J].中国癌症杂志,2011,21(3):193-196. 被引量:10
  • 9KUESPERT K,PILS S,HAUCK C R. CEACAMs:their role in physiology and pathophysiology[J].Current Opinion in Cell Biology,2006,(05):565-571.doi:10.1016/j.ceb.2006.08.008.
  • 10BLUMENTHAL R D,HANSEN H J,GOLDENBERG D M. Inhibition of adhesion,invasion,and metastasis by antibodies targeting CEACAM6(NCA-90) and CEACAM5(Carcinoembryonic antigen)[J].Cancer Research,2005,(19):8809-8817.doi:10.1158/0008-5472.CAN-05-0420.

二级参考文献30

共引文献22

同被引文献87

  • 1李醒亚,成媛,刘杰,申淑景,贾永旭.非小细胞肺癌患者血清CEA水平与EGFR-TKI疗效的关系[J].中国癌症杂志,2011,21(3):193-196. 被引量:10
  • 2Benchimol S,Fuks A,Jothy S,et al.Carcinoembryonic antigen,a human tumor marker,functions as an intercellular adhesion molecule[J].Cell,1989,57(2):327-334.
  • 3Shoji F,Yoshino I,Yano T,et al.Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas[J].Cancer,2007,110 (12):2793-2798.
  • 4Pan J B,Hou Y H,Zhang G J.Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients[J].Asian Pacific J Cancer Prey,2013,14 (2):695-700.
  • 5Tufman A,Huber R M.Biological markers in lung cancer.A clinician's perspective[J].Cancer Biomark,2010,6(3-4):123-135.
  • 6Okamoto T,Nakamura T,Ikeda J,et al.Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer[J].Eur J Cancer,2005,41 (9):1286-1290.
  • 7赵皓,施敏骅.化疗序贯TKI治疗EGFR-TKI耐药后非小细胞肺癌的临床观察[C]//中华医学会呼吸病学年会——2013第十四次全国呼吸病学学术会议论文汇编,2013:11-13.
  • 8GERBER D E,SCHILLER J H.Maintenance chemotherapy for advanced non-small-cell lung cancer:new life for an old idea[J].J Clin Oncol,2013,31(8):1009-1020.
  • 9YANC L,REN B,LI H,et al.Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients[J].Cancer Immunol Immunother,2013,62(1):65-73.
  • 10WANG Zhen,TONG Zhao-hui,LI Hong-jie,ZHAO Ting-ting,LI Xu-yan,XU Li-li,LUO Jing,JIN Mu-lan,LI Rui-sheng,WANG Chen.Semi-rigid thoracoscopy for undiagnosed exudative pleural effusions: a comparative study[J].Chinese Medical Journal,2008(15):1384-1389. 被引量:21

引证文献10

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部